A unique binding epitope for salvinorin A, a non-nitrogenous kappa opioid receptor agonist

被引:33
作者
Kane, BE
Nieto, MJ
McCurdy, CR
Ferguson, DM [1 ]
机构
[1] Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Ctr Drug Design, Minneapolis, MN 55455 USA
[3] Univ Mississippi, Dept Med Chem, University, MS 38677 USA
关键词
chimeric; kappa opioid; molecular biology; mutagenesis; salvinorin;
D O I
10.1111/j.1742-4658.2006.05212.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Salvinorin A is a potent kappa opioid receptor (KOP) agonist with unique structural and pharmacological properties. This non-nitrogenous ligand lacks nearly all the structural features commonly associated with opioid ligand binding and selectivity. This study explores the structural basis to salvinorin A binding and selectivity using a combination of chimeric and single-point mutant opioid receptors. The experiments were designed based on previous models of salvinorin A that locate the ligand within a pocket formed by transmembrane (TM) II, VI, and VII. More traditional sites of opiold recognition were also explored, including the highly conserved aspartate in TM III (D138) and the KOP selectivity site E297, to determine the role, if any, that these residues play in binding and selectivity. The results indicate that salvinorin A recognizes a cluster of residues in TM II and VII, including Q115, Y119, Y312, Y313, and Y320. Based on the position of these residues within the receptor, and prior study on salvinorin A, a model is proposed that aligns the ligand vertically, between TM II and VII. In this orientation, the ligand spans residues that are spaced one to two turns down the face of the helices within the receptor cavity. The ligand is also in close proximity to EL-2 which, based on chimeric data, is proposed to play an indirect role in salvinorin A binding and selectivity.
引用
收藏
页码:1966 / 1974
页数:9
相关论文
共 40 条
[1]  
AIKOPTA I, 1996, PROTEIN ENG, V9, P573
[2]  
Befort K, 1996, MOL PHARMACOL, V49, P216
[3]   Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2) [J].
Béguin, C ;
Richards, MR ;
Wang, YL ;
Chen, Y ;
Liu-Chen, LY ;
Ma, ZZ ;
Lee, DYW ;
Carlezon, WA ;
Cohen, BM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (11) :2761-2765
[4]   HIGH-EFFICIENCY TRANSFORMATION OF MAMMALIAN-CELLS BY PLASMID DNA [J].
CHEN, C ;
OKAYAMA, H .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (08) :2745-2752
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]   Controlling signaling with a specifically designed Gi-coupled receptor [J].
Coward, P ;
Wada, HG ;
Falk, MS ;
Chan, SDH ;
Meng, F ;
Akil, H ;
Conklin, BR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) :352-357
[7]   Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the κ-opioid receptor does not affect dynorphin A(1-13) affinity and function [J].
Ferguson, DM ;
Kramer, S ;
Metzger, TG ;
Law, PY ;
Portoghese, PS .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (07) :1251-1252
[8]   Neoclerodane diterpenes as a novel scaffold for μ opioid receptor ligands [J].
Harding, WW ;
Tidgewell, K ;
Byrd, N ;
Cobb, H ;
Dersch, CM ;
Butelman, ER ;
Rothman, RB ;
Prisinzano, TE .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (15) :4765-4771
[9]  
HJORTH SA, 1995, MOL PHARMACOL, V47, P1089
[10]   Mutational evidence for a common κ antagonist binding pocket in the wild-type κ and mutant μ[K303E] opioid receptors [J].
Jones, RM ;
Hjorth, SA ;
Schwartz, TW ;
Portoghese, PS .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (25) :4911-4914